Sleuthy Google upstart Calico forges a rare biotech collaboration on aging with Novartis-backed C4
The elusive but widely buzzed about Calico, a startup bankrolled by Google to find new therapies for aging, has hitched up with protein degeneration-focused C4 Therapeutics with plans to embark on a 5-year, cross country research collaboration.
The deal announcement is long on overarching goals, such as a preclinical focus on cancer, among other areas, but with little insight into the numbers or the work. And that’s just the way Calico likes to keep it, carefully cloaking its activities more like an IT company than any average biotech.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.